Tmplantable Atrial Defibrillator. Introduction: The purpose of our study was lo evaluate the ettect uf repeated cardioversiun with an implantable atrial defibrillator on tbe clinical outcome of patients witb atrial fibrillation.
Introduction
Recent studies in animals and humans suggest that atrial fibrillation alters tbe electrophysiologic properties of the atrium and facilitates the maintenance and recurrence of atrial fibrillation.'-^ If the electrophysiologic changes associated with atrial fibrillation can be prevented with early cardioversion. the likelihood of recurrent atrial fibrillation and its sequelae may be reduced. The implantable atrial defibrillator is an effective device for the early detection and cardioversion of atrial fibrillation.'^ The purpose of this study was to evaluate prospectively the effect of implantable atrial defibrillator tberapy on the natural bistory of atrial tibrillaiion. 
Methods

Patient Popttlation
The study population consisted of 13 men and 3 women (mean age 58 ± I 1 years) who were treated with an implantable atrial defibrillator for symptomatic, drug-refractory atrial fibrillation (Table 1) . Seven patients had no cardiovascular disease, 5 patients had hypertension. 3 patients bad coronary beart disease, and I patient had congenital heart disease. Eacb patient had recurrences of alrial fibrillation despite treatment with at least one Class I or III antiarrhythmic drug. During episodes of atrial fibrillation, 2 patients noted dizziness, 11 noted palpitations. 5 noted shortness of breath. 6 noted chest pain, and 11 noted weakness.
Prior to implantation of tbe atrial defibrillator. atrial fibrillation terminated spontaneously within 48 bours of onset in eight patients with paroxysmal atrial fibdllation. Atrial fibrillation recurred at least 2 weeks after successful external or internal cardioversion and persisted indefinitely and for at least the 1 month prior to device implantation in eigbt patients witb persistent atrial fibrillation. The patients bad paroxysmal atrial fibrillation for 80 ± 61 months (range 18 to 168), The eight patients had persistent atrial fibrillation for a mean duration of 68 -^i 119 months, and tbe most recent episode had persisted for 3.9 ± 1.9 months (range 1 to 8), There were no identifiable differences between patients with paroxysmal and persistent atrial fibrillation (Table 2) , After a detailed medical history and physical examination, all patients underwent a preprocedure evaluation consisting of a 12-lead ECG. 24-hour Holter monitoring, chest radiograph, transthoracic and transesophageal echocardiog- raphy. serum electrolyte measurements, complete blood court, and thyroid function tests. Patients with any of the following conditions were excluded from study participation: (I) reversible causes of atrial Hbrillation. such as electrolyte imbalance or hyperthyroidism; (2) clinically significant valvular beart disease or the presence of a cardiac valve prosthesis; (3) unstable angina or a myocardial infarction within the previous 6 months; (4) New York Heart Association Class III or IV heart failure during sinus rhythm; (5) echocardiograpbic evidence of left atrial thrombi; or (6) coexisting ventricular taehyanhythmias.
Implantable Atrial Defihrillator System
The ethics committee or institutional review board at botb participating centers approved the protocol. Written inft)rnicd consent was obtained from each patient. A previously described implantable atrial detibrillator (models 3000 or 3020, Guidant. St. Paul, MN. USA) was used in conjunction with either a one-or two-lead defibrillation system.' "^ Both lead systems were positioned under Muoroscopic guidance from the cephalic and/or subclavian vein. In three patients, a single passive fixation defibrillation lead was positioned in the coronary sinus (Fig. IA) . This lead had a distal defibrillation coil that was positioned in the coronary sinus and a proximal defibrillation coil that was positioned in tbe right atrium {Guidant model 7309). In 13 patients, a dual lead system was utilized (Fig. IB ). An active fixation lead with a single defibrillation coil (Guidant model 7205) was ptisitioned in the right atrium. Tbe second passive fixation lead that was positioned in the coronary sinus also had a single defibrillation coil (Guidant model 7109). A standard bipolar endocardia! ventricular pacing lead was used for R wave synchronization and ventricular pacing with each of tbe defibrillation lead systems.
The implantable atrial defibrillator performed atrial sensing and defibrillation between the right atrial and coronary sinus coil electrodes. The intracardiac atrial and ventricular electrograms were used in specific algorithms for atrial fibrillation detection and R wave synchronization.T he deviee stored the atrial and ventricular intracardiac electrograms from the six most recently identitied episodes of atrial fibrillation. Tbe stored data included how the device synchronized to the ventricular electrogram. the date and time of the onset of episodes of atrial fibrillation, and the duration of tbe 170 most recently detected atrial fibrillation episodes. Shocks were synchronized to tbe ventricular electrogram and were only delivered after an RR interval of at least 500 msec. VVI pacing was a programmable feature.
Although the implantable atrial defibrillator had three programmable therapy modes, only the monitor mode was used when patients were outside the hospital. The device was programmed to sense every 120 minutes. When the sensing sequence was initiated, atrial electrogram sensing and R wave synchronization were performed. Tbe sensing interval required approximately 2 minutes to complete, then the cycle was repeated. In the monitor mode, the device stored episode data, but did not deliver shocks. Patients were instructed to come to the hospital or clinic for each episode of symptomatic atrial fibrillation. Under physician supervision, the device was programmed to the automatic mode, and a shock was automatically delivered. Sedation with intravenous midazolam was administered at the request of the patient. Success or failure of each shock was noted. Early reinitiation of atrial fibrillation was defined as the recurrence of atrial fibrillation within I minute of a successful cardioversion."" The implantable atrial defibrillator delivered a biphasie shock with a leading-and trailing-edge duration of either 3 or 6 msec, with a maximum output of 300 V (Guidant models 3000 and 3020).
Atrial Defibrillation Threshold Testing
The atrial defibrillation threshold was determined using an up-down defibrillation protocol starting at 180 V after adequate sedation was achieved with intiavenous fentanyl and/or midazolam."^ Implantation of the device required successful conversion of atrial fibrillation to sinus rhythm with at least 1 of 3 attempts using either 260 V (Guidant model 3000) or 240 V (Guidant model 3020). Atrial defibrillation threshold testing was repeated using the same protocol I and 3 months after device implantation. When patients were in sinus rhythm, atrial fibrillation was induced with a low-intensity shock synchronized to the R wave or with rapid atrial pacing through a temporary catheter.
Implantahle Atrial Defibrillator Episode Log
The device's episode log was used to identify the duration of each episode of atrial fibrillation with an accuracy of ± 2 hours. An episode ol atrial fibrillation identified during only one sensing interval was defined as persisting for 2 bours, but actually may have persisted from I minute to 3 hours 59 minutes. The longest single episode of atrial fibrillation that could be recorded with this device was 340 hours. If 170 consecutive sensing intervals demonstrated atrial fibrillation, tben tbe episode was defined as lasting 340 hours. However, tbis observation could have been due to paroxysmal episodes of atrial fibrillation that were present during eacb sensing interval. Additionally, in this instance, the epi.stide may bave persisted beyond 340 hours.
EoUow-Up
An investigator evaluated each patient 1, 3, and 6 months after the implantable atrial defibrillator was implanted, f^uritig these outpatient visits, the device was interrogated to determine the number and total duration of atrial hbriliation episodes. A surface echocardiogram was performed during the 6-month follow-up visit lo evaluate the left atrial diameter and left ventricular ejection fraction. Lelt atrial size from the baseline and follow-up surface echocaidiograms was estimated from the parasternal long-axis view. The measurement was determined independently by two echocardiographers in a subset of 1 1 patients. The measurements obtained from each echocardiogram were within I nun in each case. From the time of atrial defibrillator implantation and throughout the study pcritid. the goal was to avoid altering antiarrhytbmic drug therapy, if possible. Aspirin or warfarin was prescribed at the discretion of tbe investigator (Table 1).
Antiarrbythmic medication remained unchanged throughout the study perit)d (Table 1) . However, the dosage was adjusted in six patients who were receiving amiodarone. The dosage of amiodarone was reduced in one patient who developed symptomatic bradycardia and in two patients in whom spontaneous episodes of atrial fibrillation could not be converted with 300 V. In the remaining three patients, tbe dosage of amiodarone was temporarily increased for 2 weeks because of two or more symptomatic episodes of atrial fibrillation per week. After atrial defibril-lator implantation, 12 patients were treated with warfarin and 2 patients were treated with aspirin (Table I) .
Statistical Analysis
Continuous variables are expressed as mean ± 1 SD and were compared using a /-test or an analysis of variance, as appropriate. Discrete variables were compared using a Chi-square test. A prospective decision was made to evaluate the data from all patients and to stratify the data according to the diagnosis of persistent or paroxysmal atrial fibrillation. Additionally, a prospective decision was made to compare the number of episodes of atrial fibrillation and total duration of atrial fibrillation that occurred during the first 3 months and second 3 months after the atrial defibriliator was implanted. P < 0.05 was considered statistically significant. 54 spontaneous episodes of atrial fibrillation (2.7 ± 2.1 shocks per episode; range 1 to II). Shock therapy from the iniptantable atrial defibriliator terminated 50 (93%) of 54 of these episodes, with 2.4 ± 1.9 shocks per atrial (ihrillation episode (range 1 to 11). A single implantable atrial defibriliator shock terminated and restored sinus rhythm during 12 (22'^ ) of the spontaneous episodes of atrial tibrillation.
Four patients had an episode of atrial Hbrillation that did not convert to sinus rhythm after 4.5 ± 2.4 shocks (range 3 to 8). Two of these four episodes spontaneously converted to sinus rhythm 1 and 2 days later. In the other two patients, the dosage of amiodarone was reduced and sinus rhythm was restored by the implantable atrial defibriliator with two shocks in each patient 2 weeks later. Three patients developed symptomatic bradycardia after shock therapy and required temporary VVI pacing from the device.
Results
Treatment of Spontaneous Episodes of Atrial Fibrillation
During the 6-month follow-up. 12 patients (75%) received implantable atrial defibriliator therapy for at least one spontaneous episode of atrial fibrillation, and 4 patients did not receive implantable atrial defibriliator therapy for a spontaneous episode ot atrial fibrillation. In I of the 4 patients who did not receive a shock from the implantable atrial defibriliator for a spontaneous episode of atrial fibrillation, atrial fibrillation did not recur after the implantable atrial defibriliator was implanted for the treatment of persistent atrial fibrillation. The remaining three patients who had a history of paroxysmal atrial fibrillation developed symptomatic atrial fibrillation, but they did nt)t come to the hospital for cardioversion hy the implantable atrial defibriliator.
The 12 patients who received implantable atrial defibriliator therapy had 54 episodes of spontaneous atrial fibrillation for which a shock frotn the device was delivered (4.5 ± 4,1 episodes per patient; range 1 to 14). Seventeen of these episodes (31%) occurred in five patients with paroxysmal atrial fibrillation. The remaining 37 episodes (69%) occurred in seven patients with persistent atrial fibrillation. A total of 136 shocks were delivered for the treatment of these
Arrhythmia Recurrences
In the first 3 months after atrial defibriliator implantation, the number of spontaneous episodes of atrial fibrillation per patient (15 ± 16) was the same as during the subsequent 3 months of follow-up (12 ± 16; P = 0.2). However, the total duration of atrial fibrillation decreased from 126 ± 172 hours during ihc second 3 months compared with 261 ± 270 hours during the initial 3 months CP = 0.01), after atrial defibriliator implantation (Fig. 2) .
There was no significant difference in the number of spontaneous atrial fibrillation episodes between patients with paroxystnal and persistent atrial fibrillation during the initial 3 months (22 ± 18 episodes per patient vs 9 ± 13 episodes per patient; P = 0.2) and subsequent 3 months (20 ± 20 episodes per patient vs 5 ± 5 episodes per patient; P = 0.08) after atrial defibriliator implantation. During the initial 3 months after device implantation, the total duration of atrial fibrillation for patients with paroxystnal atrial librillation was 135 ± 98 hours compared with 391 ± 330 hours for patients with persistent atrial fibrillation (P < 0.05). During the second 3 months alter itnplantabic atrial defibriliator implantation, the total duration of atrial fibrillation was not significantly different between patients with paroxystnal (68 ± 120 hours) and persistent alrial fibrillation (185 ± 204 hours; P = 0.2; Fig. 2 ). Subgroup analysis demonstrated that the total duration of atrial fi- 
. Total duration of atrial fibrillation (AF}for each patient during the first and second 3-month periods after the atriai defibrillator was implanted. Statistically significant p values are shown. Circles represent the mean duration (± } SD) of AF in all of the patients. Triangles and squares represent the mean (± I SD) and individual data for patients with persistent and paroxysmal atrial fibrillation, respectively.
brillation did not change significantly among patients with paroxysmal atria! fibrillation (36 ± 98 hours vs 68 ± 120 hours; P = 0.09), whereas patients with persistent atrial fibrillation bad a significant reduction in the total duration of atrial fibrillation (391 ± 330 hours vs 185 ± 204 hours; P < 0.05). Six months after implantable atrial defibrillator implantation, eacb patient was in sinus rhythm.
Echocardiographic Results
At the time of atrial defibrillator implantation, the mean left ventricular ejection fraction was 0.56 ± 0.08, and the mean left atrial diameter by eehocardiography was 4.4 ± 0.7 cm. Prior to implantation of the device, patients with persistent atrial fibrillation had a significantly larger left atrial diameter than patients with paroxysmal atrial fibrillation (4.8 ± 0,8 cm vs 4,1 ± 0.5 cm; P = 0.03; Table 2 ). After 6 months of treatment with the implantable atrial defibrillator, left ventricular ejection fraction did not change significantly (0.59 ± 0.05; P = 0.08); however, there was a significant reduction in left atrial size compared with before device implantation (4,1 ± 0.6 cm; P = 0.02; Fig. 3 ). Left atrial size did not change significantly among patients with paroxysmal atrial fibrillation (4.1 ± 0.5 cm vs 4.0 ± 0.4 cm; P = 0.2), whereas patients with persistent atrial fibrillation demonstrated a significant reduction in left atrial size (4.8 ± 0.8 cm vs 4.3 ± 0.7 cm; P < 0.05; Fig. 3 ).
Early Reinitiation of Atrial Fibrillation
Reinitiation of atrial fibrillation within 1 minute of successful cardioversion of a spontaneous episode of atrial tibrillation occurred after 11 (20%) of 54 successfully treated episodes of atrial fibrillation in 6 of the 12 patients who received treatment for a spontaneous episode of atrial fibrillation. If early reinitiation of atrial fibrillation is considered a clinical failure, then the overall clinical efficacy ol' the device was 83%. Sinus rhythm was restored after six of these episodes with acute administration of intravenous procainamide in I patient, intravenous Hecainide in 2 patients, and intravenous sotalol in 3 patients, followed immediately by cardioversitin with the device. In tbe remaining five episodes, I patient converted spontaneously to sinus rhythm 20 minutes after intravenous adtninJstration of flecainide and 4 patients converted spontaneously to sinus rhythm without further therapy within 48 hours. Implantable atrial defibrillator tberapy associated witb early reinitiation of atrial fibrillation 
Figure 4. Atriat defibriltation ttirestwtd (ADFT) in volts (V) and joules (J) determined during device implantation, and 1 and 3 months later. Soltd bars tnctude all patients: open bars include only data from patients with paroxysmal atriat fibrittation; and luuched bars include onty data from patients with persistent atriat fibrillation. Statistically significant p values are shown.
tibrillation episode compared with 2.2 ± 1.5 shocks per atrial fibrillation episode that was not associated with early reinitiation of atrial fibrillation (P = 0.02).
Atrial Defihrillation Thresholds
The mean atrial dclibrillalion thresholds were 250 ± 36 V (3.5 ± 1,3 J), 270 ± 45 V (4.3 ± 1.0 J). and 245 ± 56 V (3.6 ± 1.8 J) at implant, I month, and 3 months after device implantation, respectively (P ~ 0.6; Fig. 4 ). The mean lead impedance was 65 ± 4 H at implant and did not change during follow-up (P = 0.8). There was no significant difference in the initial atrial delibrillation threshold between patients receiving or not receiving amiodarone (255 ± 10 V vs 240 ± 15 V; P -0.5). At implant, three patients witb persistent atrial fibrillation bad an atrial defibrillation threshold > 260 V. After tbe administration of intravenous ibutilide in two patients and intravenous sotalol in one patient, an atrial defibrillation tbresbold < 260 V was achieved.
During device implantation, the atrial detibrillation threshold was significantly greater in patients witb persistent atrial fibrillation (272 ± 18 V; 4.6 ± 0.8 J) than in patients with paroxysmal atrial tibrillation (228 ± 35 V, P < 0.01; 2.5 ± 1 J, P < 0.001; Fig. 4 ). There was no significant difference in the atrial detibrillation threshold between patients with paroxysmal and persistent atrial fibrillation during tbe 1-month {248 ± 60 V vs 276 ± 18 V; P = 0.2) and 3-montb (240 ± 61 V vs 250 ± 53 V; P = 0.7) atrial defibrillation threshold determination. The shocking impedance was similar between these two groups of patients during tbe initial and subsequent atrial defibrillation tbreshold determinations (P = 0.8).
The atrial detibrillation threshold was signiticantly greater among patients witb persistent, as compared with paroxysmal, atrial fibriiiation (P < 0.01; Table 2 ). Otherwise, there was no significant correlation between the initial atrial defibrillation threshold and any identitiable clinical characteristic, including age (P = 0.7), gender (P = 0.8), duration of atrial fibrillation (P = 0.5), left ventricular ejection fraction (P = 0.3), or left atrial size (P = 0.3).
Tolerance of Shocks
Two (17%) of 12 patients did not request sedation for implantable atrial detibrillator therapy tbat was delivered for 17 spontaneous episodes of atrial fibrillation. Four patients tolerated a single atrial defibrillator sbock witbout sedation during six spontaneous episodes of atriai fibrillation, but requested sedation when more than one shock was required. The remaining six patients requested sedation for 26 spontaneous episodes of atrial fibrillation for wbicb atrial defibrillator tberapy was delivered. Sedation was acbieved witb intravenous administration of 2 to 10 mg of midazolam (5.3 ± 3.2 mg).
Complications
There were no acute complications associated witb implantation of tbe atrial defibrillator. One patient developed subclavian vein thrombosis 2 weeks after the device was implanted and was treated with warfarin. Ventricular proarrhytbmia was not observed during tbe study. No thromboembolic events were noted during the study.
Discussion
Main Findings
The major finding of this study is that maintenance of sinus rhytbm witb repeated cardioversion with an implantable atrial defibrillator in combination with antiarrhythmic drugs may favorably infiuence the natural bistory of atrial fibrillation by reducing the total duration of atrial tibrillation and reducing left atrial size in patients witb persistent atrial fibrillation.
Mechanism
Although tbe technical feasibility, safety, and efficacy of the implantable atrial detibrillator bas been reported,^-'' tbe data contained berein are the first to suggest that aggressive maintenance of sinus rhytbm with tbe implantable atrial defibrillator may alter tbe progressive nature of atrial tibrillation, may reverse at least some portion of tbe associated atrial myopatby, and support the notion that sinus rhythm predisposes to sinus rbytbm.
Previous studies in animals and bumans suggest tbat rapid cardioversion of atrial tibrillation may prevent tbe electrical remodeling that occurs with atrial fibrillation, tbat paroxysmal and persistent atrial fibrillation lead to progressive atrial enlargement, and that left atrial size correlates with the duration of atrial fibrillation.'•-•^•'^ This suggests that enlarged atria are more likely to occur in patients witb persistent atrial fibrillation and, therefore, would be more likely to demonstrate reversal of this process with maintenance of sinus rbytbm. Additionally, atrial enlargement is associated witb a greater risk of arrhythmia recurrence, as well as tbromboembolic complications.'"'-Tbe results of the present study imply that restoration and maintenance of sinus rhythm by repeated cardioversion may reverse the process of left atrial enlargement by reversing the mechanical remodeling process associated with atrial fibrillation. Tbe reduction in left atrial size and total duration of atrial fibrillation was more prominent in patients with persistent atrial tibrillation than in those with paroxysmal atrial fibrillation. The strength of these data is limited by tbe relatively small sample size, only two echocardiograpbic measurements of left atrial size, and a clinical follow-up period of only 6 months. However, additional investigation is required to determine if maintenance of sinus rhythm and a reduction in left atrial size will reduce the risk of the thromboembolic complications associated with atrial fibrillation.
Early Reinitiation of Atrial Fihrillation
Early reinitiation of atrial tibrillation occurs after successful internal dofibrillation, with t)r without an implantable atrial delibrillator, in 13% to 36% of patients.^'^-'^ A 20% incidence was noted in the present study. Atrial fibrillation is associated with atrial electrical remodeling in animals and humans and is the mechanism whereby atrial tihrillation provokes atrial fibrillation.'-^ It is reasonable to assume tbat electrical remodeling also is responsible for early reinitation of atrial fibrillation after a successtui cardioversion. In tbe present study, early reinitiation of atrial fibrillation was associated with an increased luimber of shocks per atrial fihiillation episode and a reduced overall clinical efticacy of the implantable atrial defibrillator from 93% to 83%. In tbe present study and in previous reports, intravenous administration of a Class I or Til antiarrhytbmic agent appeared to suppress the early reinitiation of atrial tibrillation in some
Concomitant Drug Therapy
Although the implantahle atrial detibrillator effectively restored sinus rhythm, the majority of patients still required chronic adjunctive antiarrhythmic therapy to reduce the frequency of atrial fibrillation or to prevent early recurrences of atrial tibrillation. Antiarrhytbmic agents also may influence the efticacy of cardioversion witb tbe implantable atrial defibriliator. In the present study, tbere was no significant difference in tbe initial atrial defibrillation threshold between patients undergoing concomitant treatment with or witbout amiodarone. However, in two patients wbo failed cardioversion, a reduction of the amiodarone dosage was associated with a reduction of the atrial defibrillation requirement In previous studies, amiodarone bad a variable etfect on the atrial detibrillation tbreshold, and intravenous sotalol and ibutilide were associated with a lower atrial defibrillation threshold."''^"
Patient Acceptance of Implantable Atrial Defibrillator Therapy
For the implantable atrial defibrillator to be a viable clinical tool, the discomfort associated with device shocks must be manageable. In the present study, only 20% of patients underwent atrial detibrillator sbocks without sedation. The discomfort associated witb the shocks may be related to the number of delivered shocks and not to tbe intensity of tbe individual shocks.^' Tberefore, to improve patient acceptance of the implantable atrial defibrillator. the first shock energy should be associated with a high probability of successful defibrillation. Successful defibrillation is a function of many factors, including electrode design and position, shock waveform and polarity, concomitant antiarrhythmic drug therapy, and clinical factors.'^•*'^*' Maximizing the defibrillation system may increase the number of patients who do not require sedation. Finally, the use of an oral sedative witb rapid absorption and a short duration of action prior to implantable atrial defibrillator tberapy may increase patient acceptancesL imitations The major limitation of this study is that, depending on when the atrial fibrillation episode occurred relative to tbe sensing cycle, some episodes of atrial tibrillation may not have been sensed while multiple episodes may have been defined as a single episode. Due to this device limitation, the duration and number of episodes may bave been overcounted or undercounted. However, overcounting and undercounting most likely occurred randomly throughout the study, thereby reducing or eliminating the importance of this limitation. The second limitation of tbis study is that the .serial echocardiograms and atrial defiibrillation thresholds were not performed at the same points in time. This limits the ability to correlate tlie findings from these two tests. Finally, the natural history of persistent and paroxysmal atrial fibrillation is not well defined.
Clinical Implications
The results of the present study suggest that repeated cardioversion with an implantable atrial defibrillator might reverse tbe process of mechanical atrial remodeling in patients witb persistent atrial fibrillation. The use of the implantable atrial defihrillator in tbe patient activated or automatic mode may intensify this effect by providing prompter tberapy for atrial fibrillation. The impiantable atrial defibritlator may have a greater effect on the natural bistory of atrial fibrillation in patients with persistent atria! fibrillation as opposed to patients with paroxysmal atrial fibrillation.
